Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

C4 Therapeutics (CCCC) Shares Outstanding (Weighted Average): 2019-2024

Historic Shares Outstanding (Weighted Average) for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $70.6 million.

  • C4 Therapeutics' Shares Outstanding (Weighted Average) rose 2.64% to $71.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.2 million, marking a year-over-year increase of 2.64%. This contributed to the annual value of $70.6 million for FY2024, which is 43.24% up from last year.
  • According to the latest figures from FY2024, C4 Therapeutics' Shares Outstanding (Weighted Average) is $70.6 million, which was up 43.24% from $49.3 million recorded in FY2023.
  • In the past 5 years, C4 Therapeutics' Shares Outstanding (Weighted Average) registered a high of $70.6 million during FY2024, and its lowest value of $43.0 million during FY2020.
  • Over the past 3 years, C4 Therapeutics' median Shares Outstanding (Weighted Average) value was $49.3 million (recorded in 2023), while the average stood at $56.3 million.
  • Data for C4 Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 43.24% (in 2024) over the last 5 years.
  • C4 Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $43.0 million in 2020, then climbed by 13.01% to $48.6 million in 2021, then increased by 0.68% to $49.0 million in 2022, then climbed by 0.66% to $49.3 million in 2023, then spiked by 43.24% to $70.6 million in 2024.